



UNIVERSITY OF LEEDS

This is a repository copy of *What does NICE have to say about antimicrobial prescribing to the dental community?*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/95567/>

Version: Accepted Version

---

**Article:**

Thompson, W and Sandoe, J (2016) What does NICE have to say about antimicrobial prescribing to the dental community? *British Dental Journal*, 220 (4). pp. 193-195. ISSN 0007-0610

<https://doi.org/10.1038/sj.bdj.2016.137>

---

**Reuse**

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

## **What does NICE have to say about antimicrobial prescribing to the dental community?**

**W. Thompson (Lancaster) and J.A.T. Sandoe (Leeds)**

### Abstract

Slowing the emergence of antimicrobial resistance is essential to ensuring antimicrobials remain an effective treatment for infections. Professor Dame Sally Davies, the UK Chief Medical Officer has compared the threat posed by resistance to that from global terrorism. Antimicrobial use is a key driver of antimicrobial resistance, so reducing unnecessary prescriptions is a high priority. NICE has developed guidance aimed at optimising prescribing within publically-funded health and care services. With primary care dentists responsible for 5% of all NHS antibacterial prescriptions, the dental community has a role to play in guarding the effectiveness of antibacterial drugs. This article describes three recent NICE publications that have implications for dentists. Antimicrobial Stewardship: Systems and Processes (NG 15) is an overarching guideline for the NHS aimed at commissioners and providers of health and care services, together with more specific guidance for prescribers. Prophylaxis against infective endocarditis (CG64) was reissued in 2015 following a review of the latest evidence prompted by concerns that the incidence of infective endocarditis had increased since initial publication of CG64 in 2008. Changing risk-related behaviours of the public in relation to expectations for antimicrobial prescriptions (PHG89) is currently in production. This paper outlines the key recommendations from these NICE guidelines as they relate to the dental community.

### In brief:

- Describes NICE guidance on antimicrobial prescribing
- Considers some of the implications of the guidance for commissioners and providers of NHS dental care services in England.
- Highlights key recommendations for dental prescribers.

### Introduction

Antimicrobial resistance (AMR) has risen alarmingly over the last 40 years and inappropriate use of antimicrobials is a key driver<sup>i</sup>. The consequences of resistance include increased treatment failure for common conditions and fewer treatment options when antimicrobials are vital, such as during certain cancer treatments<sup>ii</sup>. All prescribers of antimicrobials have a role to play in guarding their use, so that they continue to be effective.

Across NHS England, primary care accounted for 82% and secondary care for 18% (11% hospital inpatients and 7% outpatients) of antibacterial prescriptions<sup>iii</sup> during 2014. NHS dentists prescribe more antibacterial drugs than any other medication<sup>iv</sup>. Some 3.7 million antibacterial prescriptions were dispensed by pharmacists in England<sup>v</sup> for patients seen in dental practices, equating to 5% of all antibacterial prescriptions issued in the NHS in 2014<sup>vi</sup>. Dentists clearly have an important role to play in the stewardship of antimicrobials but particularly of antibacterial agents.

In August and September 2015, the National Institute for Health and Care Excellence (NICE) published three guidance documents (new guidance, draft guidance, and updated guidance) of which NHS dentists working in England need to be aware when prescribing antimicrobials:

- Antimicrobial Stewardship: Systems and processes for effective antimicrobial medicine use – NG15 (August 2015)<sup>vii</sup>
- Antimicrobial Stewardship: Changing risk-related behaviours in the general population - PHG 89 (draft for consultation September 2015)<sup>viii</sup>
- Prophylaxis against infective endocarditis: Antimicrobial prophylaxis against infective endocarditis for adults and children undergoing interventional procedures – addendum to CG64 (September 2015)<sup>ix</sup>

Each of these documents has important recommendations for antimicrobials of relevance to prescribers, providers and commissioners of NHS dental services. The aim of this article is to outline some key aspects and new requirements.

### **Antimicrobial Stewardship (NG15)**

Antimicrobial stewardship (AMS) is an overarching term for systems and processes to optimise the use of antimicrobials and thereby improve patient outcomes and reduce AMR. While the General Dental Council (GDC) standards/guidance<sup>x</sup> and Care Quality Commission (CQC) Fundamental Standards<sup>xi</sup> apply to all dentists practising in the UK, these new documents introduce more detailed requirements for those working with NHS patients in England. GDC, CQC and NG15 all specify that recognised guidelines should be followed when prescribing antimicrobials, but leave it up to the individual dentist to decide which guidance to choose. Evidence-based guidance on antibiotic prescribing for general dental practitioners has been published by the Faculty of General Dental Practice (UK) (FGDP)<sup>xii</sup>. Guidance is also available in the British National Formulary (BNF)<sup>xiii</sup> and there is a more user-friendly presentation of this information by the Scottish Dental Clinical Effectiveness Programme (SDCEP)<sup>xiv</sup>. FGDP, BNF and SDCEP guidance documents are all available online for free; links are included in the reference section to this paper.

The NG15 recommendations which relate to dental prescribers are set out in Box 1. Because the recommendations have been written to be relevant across all primary and secondary care health and social care settings of the NHS, the terminology may at times appear unfamiliar. The onus is, therefore, on dentists to engage actively and consider how best to embed the concepts into routine practice. For example, when choosing an antibacterial, the risk of selecting for organisms causing health-care associated infections, such as *Clostridium difficile* infection (CDI), should be considered; if a dentist contemplates prescribing clindamycin its association with CDI<sup>xv</sup> is relevant and should be taken into account. Another of the NG15 recommendations states that an immediate prescription should not be given for self-limiting conditions; careful consideration is required, therefore, to decide whether prescribing aciclovir for an oral herpes simplex infection is appropriate.

In addition to recommendations for prescribers, NG15 also includes organisational-level recommendations for commissioners concerning the infrastructure to deliver and monitor AMS. Colleagues may also be interested in NICE's recommendations for the commissioners and providers of NHS services. Unlike the recommendations for prescribers, which are largely already addressed within existing requirements for dentists, the recommendations for commissioners and providers are not yet covered in all parts of the country in the dental context. Recommendations in this section include fostering of an open and transparent culture with regard to antimicrobial prescribing and encouraging senior health professionals to

promote AMS within their teams, recognising the influence that senior prescribers can have on the prescribing practices of colleagues. Further recommendations for commissioners and providers from NG15 are set out in Figure 2.

### **Antimicrobial Stewardship – Changing Risk-Related Behaviour in the General Population – draft public health guideline (PHG89)**

NICE is currently developing public health guidance which aims to help reduce AMR occurring and to stop it spreading by considering interventions to change people's behaviour. This includes making the general public aware of the importance of using antimicrobials correctly and the dangers associated with their overuse and misuse. Most of the draft guidance relates to local, national and international initiatives, such as the UK Antibiotic Guardian ([www.antibioticguardian.com](http://www.antibioticguardian.com)) initiative as part of European Antibiotic Awareness Day (18 November each year). Dentists are encouraged to play their role as health care professionals in championing this agenda and to make their pledge on the Antibiotic Guardian website. Options are available for members of the public, students and educators as well as healthcare professionals. Options for dentists to choose between are:

- I will consider drainage for dental infections before issuing an antibiotic.
- I will discuss with patients the importance of antimicrobial resistance and encourage them to take the Antibiotic Guardian quiz and make a pledge to become an antibiotic guardian.
- When I see a patient with dental pain, I will discuss methods of controlling symptoms rather than prescribing antibiotics as a first course of action.

### **Prophylaxis against infective endocarditis (CG64)**

NICE has recently updated its guidance on antibiotic prophylaxis for infective endocarditis (CG64). Before it first published this guidance in 2008, NHS dentists in England prescribed some 130,000 prophylactic antimicrobial doses per year (or 10,900 per month<sup>xvi</sup>). Although this was a small proportion of the total number of antimicrobials prescribed by NHS dentists, this still represented a substantial selective pressure for development of AMR. After the introduction of CG64, prescribing of prophylactic antimicrobials for patients at risk of infective endocarditis fell dramatically.

In 2014, a study by Dayer et al<sup>xvii</sup> published in *The Lancet* investigating the impact of CG64, concluded that the incidence of infective endocarditis had increased significantly following the introduction of the NICE guideline. NICE initiated an immediate review of the latest evidence and the findings of its committee (which included topic experts in cardiology, dentistry and microbiology) were published in September 2015 as an updated guideline (only one section was updated and this was published as an addendum to the guideline)<sup>xviii</sup>. NICE identified a long-standing increase in the incidence of infective endocarditis across the world, not just in the UK. Independent expert statistical analysis of the Dayer paper undertaken as part of the evidence review by NICE found a high risk of bias; NICE concluded that there were many possible explanations for the increase in incidence and further research was needed. As a result, NICE guidance on antimicrobial prophylaxis against infective endocarditis currently remains as per the 2008 guidance. An additional research recommendation was made: "Does antibiotic prophylaxis in those at risk of developing infective endocarditis reduce the incidence of infective endocarditis when given before a defined interventional procedure?"

The key part of CG64 (2008) for dentists remains the importance of:

- investigating and treating promptly any episodes of infection in people at risk of infective endocarditis; and
- giving clear and consistent advice to patients about prevention, including the importance of maintaining good oral health.

### Summary

Antimicrobial resistance is a current and growing problem; dentists have an important role to play in reducing its development through improved antimicrobial stewardship. By optimising antimicrobial use, these guidelines aim to ensure the continued effectiveness of antimicrobial medication into the future without needing to treat patients with more broad spectrum and potentially toxic antimicrobials. For NHS prescribers in England, these guidelines are essential; for other prescribers, they provide a useful source of evidence-based guidance on antimicrobials.

### Declarations

Wendy Thompson is a general dental practitioner and is studying for a PhD (University of Leeds). During 2014/5, she was a member of the NICE AMS Guideline Development Group and is currently a member of the NICE Quality Standard Advisory Committee on AMS.

Dr Jonathan Sandoe is Associate Clinical Professor of Microbiology (University of Leeds) and Honorary Consultant Microbiologist at Leeds Teaching hospitals NHS Trust. In 2007/8 he was a member of the NICE CG64 Guideline Development Group and during 2015 was a member of the NICE Standing Committee A which reviewed CG64 on prophylaxis for patients at risk of infective endocarditis.

### Figures

#### Recommendations for Prescribers

Below are the recommendations for prescribers from NG15 which are most relevant to dentists

1.1.23 When prescribing antimicrobials, prescribers should follow local (where available) or national guidelines on:

- **prescribing the shortest effective course**
- the most appropriate dose
- route of administration.

**1.1.24 When deciding whether or not to prescribe an antimicrobial, take into account the risk of antimicrobial resistance for individual patients and the population as a whole.**

1.1.25 When prescribing any antimicrobial, undertake a clinical assessment and document the clinical diagnosis (**including symptoms**) in patient's record and clinical management plan.

1.1.26 Prescribers should take time to discuss with the patient and/or their family members or carers (as appropriate):

- The likely nature of the condition

- Why an antimicrobial might not be the best option
  - Alternative options to prescribing an antimicrobial
  - **Their views on antimicrobials, taking into account their priorities or concerns for their current illness and whether they want or expect an antimicrobial**
  - **The benefits and harms of immediate antimicrobial prescribing**
  - **What they should do if their condition deteriorates (safety netting advice) or they have problems as a result of treatment**
  - **Whether they need any written information about their medicines and any possible outcomes.**
- 1.1.32 When an antimicrobial is a **treatment option**, document in the patient's record (electronically wherever possible):
- the reason for prescribing, **or not prescribing**, an antimicrobial
  - the plan of care as discussed with the patient, their family member or carer (as appropriate), including the planned duration of any treatment.
- 1.1.33 **Do not issue an immediate prescription for an antimicrobial to a patient who is likely to have a self-limiting condition.**
- 1.1.34 If immediate antimicrobial prescribing is not the most appropriate option, discuss with the patient, their family member or carer (as appropriate) other options such as:
- Self-care with over-the-counter preparations
  - **Back up (delayed) prescribing**
  - Other non-pharmacological interventions, such as draining the site of infection
- 1.1.35 When a decision is taken to prescribe an antimicrobial has been made, take into account the benefits and harms for an individual patient associated with the particular antimicrobial, including:
- Possible interactions with other medicines or any food and drink
  - The patient's other illnesses, for example, the need for dose adjustment in a patient with renal impairment
  - Any drug allergies (these should be documented in the patient's record)
  - **The risk of selection for organisms causing health-care associated infections, for example *C. difficile***
- 1.1.36 When prescribing is outside national guidelines, document the reason for the decision.

**Figure 1:** Selected recommendations from NG15 relevant to dental prescribers.<sup>vii</sup>

## Recommendations for commissioners and providers

Below are the NICE recommendations for commissioner and providers concerning the establishment and operation of antimicrobial stewardship programmes across all health and social care settings.

- 1.1.1 Commissioners should ensure that antimicrobial stewardship operates across all care settings as part of an antimicrobial stewardship programme.
- 1.1.2 Establish an antimicrobial stewardship programme, taking account of the resources needed to support antimicrobial stewardship across all care settings.
- 1.1.3 Consider including the following in an antimicrobial stewardship programme:
  - Monitoring and evaluating antimicrobial prescribing and how this relates to resistance patterns
  - Providing regular feedback to individual prescribers in all care settings about:
    - their antimicrobial prescribing, for example by using professional regulatory numbers for prescribing as well as prescriber (cost centre) codes
    - patient safety incidents relating to antimicrobial use, including hospital admissions for potentially avoidable life-threatening infections, infections with *C. difficile* or adverse drug reactions such as anaphylaxis
  - providing education and training to health and social care practitioners about antimicrobial stewardship and antimicrobial resistance
  - Integrating audit into existing quality improvement programmes.

Further recommendations for commissioners and providers about the systems, processes and interventions to implement and embed AMS are also detailed in NG15.

## References

- 
- <sup>i</sup> Patient Safety Alert. Stage Two: Addressing antimicrobial resistance through implementation of an antimicrobial stewardship programme. 18 August 2015; <https://www.england.nhs.uk/wp-content/uploads/2015/08/psa-amr-stewardship-prog.pdf>
- <sup>ii</sup> Davies, S. Annual Report of the Chief Medical Officer 2011: Volume Two. Infections and the Rise of Antimicrobial Resistance (2013); <https://www.gov.uk/government/publications/chief-medical-officer-annual-report-volume-2>.
- <sup>iii</sup> English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) 2010 to 2014 – Report 2015 (2015); <https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report>.
- <sup>iv</sup> Prescribing by Dentists. England, 2014; [http://www.hscic.gov.uk/catalogue/PUB17425/pres\\_dent\\_eng\\_2014\\_rep.pdf](http://www.hscic.gov.uk/catalogue/PUB17425/pres_dent_eng_2014_rep.pdf).
- <sup>v</sup> Ibid.
- <sup>vi</sup> English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) 2010 to 2014 – Report 2015 (2015); <https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report>.
- <sup>vii</sup> Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use NG15(2015); <https://www.nice.org.uk/guidance/ng15>.

---

<sup>viii</sup> Antimicrobial stewardship - changing risk-related behaviours in the general population (draft) (2015); <https://www.nice.org.uk/guidance/indevelopment/gid-phg89>.

<sup>ix</sup> Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures CG64 (2008). <https://www.nice.org.uk/guidance/cg64>

<sup>x</sup> Guidance on prescribing medicines (2013); <https://www.gdc-uk.org/Dentalprofessionals/Standards/Documents/Guidance%20Sheet%20Guidance%20on%20Prescribing%20Medicines%20September%202013%20v2.pdf>.

<sup>xi</sup> How CQC regulates: primary care dental services. Provider handbook (2015); [http://www.cqc.org.uk/sites/default/files/20150611\\_dental\\_care\\_provider\\_handbook.pdf](http://www.cqc.org.uk/sites/default/files/20150611_dental_care_provider_handbook.pdf).

<sup>xii</sup> Antimicrobial Prescribing for General Dental Practitioners (updated 2014); <http://www.fgdp.org.uk/OSI/open-standards-initiative.ashx>.

<sup>xiii</sup> British National Formulary (2015); <https://www.evidence.nhs.uk/formulary/bnf/current>

<sup>xiv</sup> Drug Prescribing for Dentistry (updated 2014); <http://www.sdcep.org.uk/published-guidance/drug-prescribing/>.

<sup>xv</sup> Thornhill, M.H., Dayer, M.J., Prendergast, B., Baddour, L.M., Jones, S., Lockhart, P.B. (2015) Incidence and nature of adverse reactions to antibiotics used as endocarditis prophylaxis. *Journal of Antimicrobial Chemotherapy*; 70(8):2382-8.

<sup>xvi</sup> Dayer, M.J., Jones, S., Prendergast, B., Baddour, L.M., Lockhart, P.B., Thornhill, M.H. (2015) Incidence of infective endocarditis in England, 2000-2013: a secular trend, interrupted time-series analysis. *The Lancet*; 385(9974): 1219-1228.

<sup>xvii</sup> Ibid.

<sup>xviii</sup> Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures CG64 (updated 2015); <https://www.nice.org.uk/guidance/cg64>.